Communiqués Jazz Pharmaceuticals plc

Actions

JAZZ

IE00B4Q5ZN47

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
222,45 ^USD	-3,78%		-3,92%	+30,85%

14:13	Jazz Pharmaceuticals plc : RBC Capital Markets réitère son opinion positive sur le titre	ZM
05/10	Un initié de Jazz Pharmaceuticals a vendu des actions pour 1 381 980 dollars, selon un récent dépôt auprès de la SEC	MT

Communiqués

15/09	Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences	PR
02/09	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences	PR
31/08	Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA	PR
27/08	Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases	PR
26/08	Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases	PR
25/08	U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma	PR
10/08	Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio	PR
03/08	Jazz: Q2 Earnings Snapshot	AQ
03/08	Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results	PR
20/07	Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026	PR
17/06	Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav on Patient Outcomes across Narcolepsy and Idiopathic Hypersomnia	AQ
16/06	Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia	PR
12/06	Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer	PR
05/06	Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia	AQ
04/06	Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia	PR
27/05	Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA	PR
12/05	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences	PR
06/05	Jazz Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
06/05	Jazz Pharmaceuticals : 1Q26 Earnings Presentation FINAL	PU
05/05	Jazz: Q1 Earnings Snapshot	AQ
05/05	Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results	PR
27/04	Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA	PR
21/04	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026	PR
21/04	Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)	PR
09/04	Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting	PR